Seres Therapeutics (MCRB)
NASDAQ:MCRB

Seres Therapeutics (MCRB) Stock Price & Analysis

660 Followers

MCRB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.50 - $9.49
Previous Close$4.87
Volume444.79K
Average Volume (3M)2.99M
Market Cap
$622.24M
Enterprise Value$679.05M
Total Cash (Recent Filing)$106.54M
Total Debt (Recent Filing)$162.71M
Price to Earnings (P/E)-2.1
Beta0.65
Aug 01, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.31
Shares Outstanding127,901,391
10 Day Avg. Volume2,210,607
30 Day Avg. Volume2,993,013
Standard Deviation0.82
R-Squared0.03
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)-10.94
Price to Sales (P/S)-1193.26
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue132.81
Enterprise Value/Gross Profit95.26
Enterprise Value/Ebitda-2.68
Forecast
Price Target Upside109.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.

---

MCRB FAQ

What was Seres Therapeutics’s price range in the past 12 months?
Seres Therapeutics lowest stock price was $2.50 and its highest was $9.49 in the past 12 months.
    What is Seres Therapeutics’s market cap?
    Currently, no data Available
    When is Seres Therapeutics’s upcoming earnings report date?
    Seres Therapeutics’s upcoming earnings report date is Aug 01, 2023 which is in 57 days.
      How were Seres Therapeutics’s earnings last quarter?
      Seres Therapeutics released its earnings results on May 09, 2023. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.55 by -$0.02.
        Is Seres Therapeutics overvalued?
        According to Wall Street analysts Seres Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Seres Therapeutics pay dividends?
          Seres Therapeutics does not currently pay dividends.
          What is Seres Therapeutics’s EPS estimate?
          Seres Therapeutics’s EPS estimate is $0.52.
            How many shares outstanding does Seres Therapeutics have?
            Seres Therapeutics has 127,901,390 shares outstanding.
              What happened to Seres Therapeutics’s price movement after its last earnings report?
              Seres Therapeutics reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.55. Following the earnings report the stock price went up 0.18%.
                Which hedge fund is a major shareholder of Seres Therapeutics?
                Among the largest hedge funds holding Seres Therapeutics’s share is Flagship Pioneering Inc.. It holds Seres Therapeutics’s shares valued at 131M.

                  ---

                  Seres Therapeutics Stock Smart Score

                  The Seres Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Seres Therapeutics

                  Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

                  ---

                  Top 5 ETFs holding MCRB

                  Name
                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  $14.46M
                  8
                  iShares Biotechnology ETF
                  $3.40M
                  8
                  Vanguard Health Care ETF
                  $1.69M
                  8
                  iShares Core S&P Total U.S. Stock Market ETF
                  $463.37K
                  8
                  Middlefield Healthcare Dividend ETF Registered
                  $341.45K
                  8
                  Up to five ETFs with an Outperform Smart Score that hold MCRB. The ETFs are listed according to market value of MCRB within the ETF

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  ACADIA Pharmaceuticals
                  Selecta Biosciences
                  Prothena
                  Kala Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis